High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

Pharmacogenetics

Volumn 14, Issue 7, 2004, Pages 429-440

  Niemi, Mikko ^a   Schaeffeler, Elke ^a   Lang, Thomas ^b   Fromm, Martin F ^a   Neuvonen, Mikko ^c   Kyrklund, Carl ^c   Backman, Janne T ^c   Kerb, Reinhold ^b   Schwab, Matthias ^a   Neuvonen, Pertti J ^c   Eichelbaum, Michel ^a   Kivistö, Kari T ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b Epidauros Biotechnologie AG   (Germany)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

ABCB1; ABCC2; MDR1; MRP2; OATP B; OATP C; Pharmacokinetics; Pravastatin; SLCO1B1; SLCO2B1

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER; PRAVASTATIN;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TRANSPORT; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AMINO ACID SUBSTITUTION; AREA UNDER CURVE; EXONS; FEMALE; FINLAND; GENE FREQUENCY; HAPLOTYPES; HETEROZYGOTE DETECTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTRONS; MALE; ORGANIC ANION TRANSPORT POLYPEPTIDE C; POLYMORPHISM, SINGLE NUCLEOTIDE; PRAVASTATIN; REFERENCE VALUES;

EID: 3242808852     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fpc.0000114750.08559.32     Document Type: Article

References (56)

1. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41:343-370.
2. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63:332-341.
3. Singhvi SM, Pan HY, Morrison RA, Willard DA. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990; 29:239-243.
4. Yamazaki M, Akiyama S, Ni'Inuma K, Nishigaki R, Sugiyama Y. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos 1997; 25:1123-1129.
5. König J, Nies AT, Cui Y, Leier I, Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1999; 1461:377-394.
6. Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotetn): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75:13-33.
7. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 2003; 43:285-307.
8. Wu X, Whitfield LR, Stewart BH. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res 2000; 17:209-215.
9. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999; 16:408-414.
10. Kobayashi D, Nozawa T, Imai K, Nezu JI, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 2003; 306:703-708.
11. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH. Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 1991; 19:740-748.
12. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999; 274:37161-37168.
13. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 2001; 297:861-867.
14. Hatanaka T. Clinical pharmacokinetics of pravastatin. Mechanisms of pharmacokinetic events. Clin Pharmacokinet 2000; 39:397-412.
15. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, et al. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos 1999; 27:173-179.
16. Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, et al. Small intestinal metabolism of the 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitor lovastatin and comparison with pravastatin. J Pharmacol Exp Ther 1999; 291:131-139.
17. Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996; 50:209-215.
18. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994; 55:481-485.
19. Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994; 22:849-857.
20. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol 1991; 32:624-626.
21. Back DJ, Tjia JF, Karbwang J, Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol 1988; 26:23-29.
22. Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, Trager WF. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos 1996; 24:610-614.
23. Kantola T, Backman JT, Niemi M, Kivistö KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000; 56:225-229.
24. Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 2004; 75:101-109.
25. Tamai I, Safa AR. Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J Biol Chem 1990; 265:16509-16513.
26. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, et al. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol 1999; 56:1219-1228.
27. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 2003; 304:610-616.
28. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-3478.
29. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwartz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70:189-199.
30. Kimchi-Sarfaty C, Gribar JJ, Gottesman MM. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. Mol Pharmacol 2002; 62:1-6.
31. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13:481-494.
32. Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in OATP-C. Identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001; 276:35669-35675.
33. Nozawa T, Nakajima M, Tamai I, Noda K, Nezu JI, Sai Y, et al. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2002; 302:804-813.
34. Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM, et al. A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem 2002; 277:43058-43063.
35. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003; 73:554-565.
36. Pauli-Magnus C, Meier PJ. Pharmacogenetics of hepatocellular transporters. Pharmacogenetics 2003; 13:189-198.
37. Xie HG, Kim RB, Wood AJJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41:815-850.
38. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 2001; 358:383-384.
39. Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther 1999; 66:118-127.
40. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73:538-544.
41. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2004; 57:181-187.
42. Rosner B. Descriptive statistics. In: Fundamentals of Biostatistics, 4th edn. Belmont, CA: Duxbury Press; 1995.
43. Ogawa K, Hasegawa S, Udaka Y, Nara K, Iwai S, Oguchi K. Individual difference in the pharmacokinetics of a drug, pravastatin, in healthy subjects. J Clin Pharmacol 2003; 43:1268-1273.
44. Rieder MJ, Taylor SL, Tobe VO, Nickerson DA. Automating the identification of DNA variations using quality-based fluorescence resequencing: analysis of the human mitochondrial genome. Nucleic Acids Res 1998; 26:967-973.
45. Nickerson DA, Tobe Vo, Taylor SL. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 1997; 25:2745-2751.
46. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68:978-989.
47. Nebert DW. Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology. Pharmacogenetics 2000; 10:279-290.
48. Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 2002; 12:529-534.
49. Johne A, Köpke K, Gerloff T, Mai I, Rietbrock S, Meisel C, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002; 72:584-594.
50. Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev 2002; 54:1311-1331.
51. Itoda M, Saito Y, Soyama A, Saeki M, Murayama N, Ishida S, et al. Polymorphisms in the ABCC2 (CMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28. Drug Metab Dispos 2002; 30:363-364.
52. Triscari J, O'Donnell D, Zinny M, Pan HY. Gastrointestinal absorption of pravastatin in healthy subjects. J Clin Pharmacol 1995; 35:142-144.
53. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 2003; 304:223-228.
54. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289:1681-1690.
55. Pazzucconi F, Dorigotti F, Gianfranceschi G, Campagnoli G, Sirtori M, Franceschi G, et al. Therapy with HMG CoA reductase inhibitors: characteristics of the long term permanence of hypocholesterolemic activity. Atherosclerosis 1995; 117:189-198.
56. Simonson SG, Schneck DW, Martin PD, Mitchell PD, Jarcho JA, Raza A. Rosuvastatin pharmacokinetics in heart-transplant recipients administered cyclosporin [abstract]. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics, 24-28 June 2003, Istanbul. Berlin: Springer-Verlag; 2003, p. 135.